Everything below concerns hGH fragment. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-11-15. Numbers and descriptions here follow the published literature rather than marketing material.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
| Property | Value | Notes |
|---|---|---|
| Common synonym | hGH fragment 176-191 | Refers to the C-terminal segment |
| Appearance | White to off-white powder | Typically supplied lyophilized |
| Solubility | Soluble in water and aqueous buffers | Confirm with technical data |
| Typical storage temperature | -20 °C for dry powder | Protect from moisture and light |
| Common analytical method | RP-HPLC with UV detection | Often paired with mass spectrometry |
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
== Diagnosis == Diagnosis is fourfold: History and physical examination, elevation of creatine kinase, electromyograph (EMG) alteration, and a positive muscle biopsy. The hallmark clinical feature of polymyositis is proximal muscle weakness, with less important findings being muscle pain and dysphagia. Cardiac and pulmonary findings will be present in approximately 25% of cases of patients with polymyositis. Sporadic inclusion body myositis (sIBM) is often misdiagnosed as polymyositis or dermatomyositis but it can be differentiated as myositis that does not respond to treatment is likely IBM. sIBM comes on over months to years; polymyositis comes on over weeks to months. Polymyositis tends to respond well to treatment, at least initially; IBM does not.
HNO3 + 2 H2SO4 ⇌ NO+2 + H3O+ + 2 HSO−4 The thermal stabilities of nitrates (involving the trigonal planar NO−3 anion) depends on the basicity of the metal, and so do the products of decomposition (thermolysis), which can vary between the nitrite (for example, sodium), the oxide (potassium and lead), or even the metal itself (silver) depending on their relative stabilities. Nitrate is also a common ligand with many modes of coordination. Finally, although orthonitric acid (H3NO4), which would be analogous to orthophosphoric acid, does not exist, the tetrahedral orthonitrate anion NO3−4 is known in its sodium and potassium salts:
==== Royal Arch Masonry ==== On February 19, 1907, Royal Arch Masonry Island Chapter No. 1 was established and granted dispensation by the General Grand Chapter of Royal Arch Masonry. On April 4, 1907, the Companions of Island Chapter No. 1 created Island Chapter U. D. On December 17, 1907, it was officially constituted under Marcus Endel, the past Grand High Priest of Florida. In 1909, High Priest R. B. Armour and the King of the Chapter U. D. visited the headquarters of the General Grand Chapter and received the charter of Island Chapter No. 1. By 1951, there were 153 members of Royal Arch Masonry in Cuba.
Sources: en.wikipedia.org
The capture and marking of birds enable detailed studies of life history. Techniques for capturing birds are varied and include the use of bird liming for perching birds, mist nets for woodland birds, cannon netting for open-area flocking birds, the bal-chatri trap for raptors, decoys and funnel traps for water birds.
==== Education ==== Diabetes management for children requires the integration of the family and health care team to be committed and continuous for promotion of self-management. A health care team may include a pediatric endocrinologist or physician trained in pediatric diabetes, a diabetes specialist nurse, a registered dietitian, a psychologist, a social worker, and child life specialist. The goal of the health care team and child's family is to empower the child to make informed decisions for health‐promoting lifestyle choices.
=== Food products === Naturally occurring melatonin has been reported in foods including tart cherries to about 0.17–13.46 ng/g, bananas, plums, grapes, rice, cereals, herbs, olive oil, wine, and beer. The consumption of milk and sour cherries may improve sleep quality. When birds ingest melatonin-rich plant feed, such as rice, the melatonin binds to melatonin receptors in their brains. When humans consume foods rich in melatonin, such as banana, pineapple, and orange, the blood levels of melatonin increase significantly.
== External links == Our Lead Asset: KH-001 - Our Work - Kadence Bio New potential treatment for premature ejaculation – KH-001 by Kadence Bio - r/PrematureEjaculation - Reddit Kanna KH 001 - Does anyone have any information about this? - r/PrematureEjaculation - Reddit
Sources: en.wikipedia.org
MyCoPortal, described by Miller and Bates as a portal providing access to digitized specimen data from participating fungaria, forms part of a broader effort to make fungal specimen information discoverable online. By 2021, the portal was reported to contain 7,394,281 occurrence records from collections spanning universities, botanic gardens, museums, and government agencies. Linked specimen metadata and sequence data can be aggregated through biodiversity portals such as GBIF, BISON, iDigBio, and MyCoPortal to support mapping, biodiversity research, and the tracking of disease records over time. The Macrofungi Collection Consortium, a National Science Foundation-funded digitization project, resulted in the digitization of approximately 1.25 million United States macrofungal specimens between 2012 and 2017. The AMUNATCOLL project digitized the Szulczewski fungarium and other natural history collections at Adam Mickiewicz University, providing open access to high-quality scans and metadata. Digitization can be extended by linking specimen records to derivative data such as gene sequences and images, keeping disparate evidence connected to a specimen record over time. Specialized collection portals can also integrate specimen records, images, georeferences, checklists, and synonymy management; for example, the Consortium of Lichen Herbaria reported more than 3.5 million occurrence records from 181 participating institutions and personal collections in 2023.
A group or series of case reports involving patients who were given similar treatment. Reports of case series usually contain detailed information about the individual patients. This includes demographic information (for example, age, gender, ethnic origin) and information on diagnosis, treatment, response to treatment, and follow-up after treatment. (NCI) Case-control study
=== Southeast Asia === Soybeans were mentioned as kadêlê (modern Indonesian term: kedelai) in an old Javanese manuscript, Serat Sri Tanjung, which dates to 12th- to 13th-century Java. By the 13th century, the soybean had arrived and cultivated in Indonesia; it probably arrived much earlier however, carried by traders or merchants from Southern China. The earliest known reference to it as "tempeh" appeared in 1815 in the Serat Centhini manuscript. The development of tempeh fermented soybean cake probably took place earlier, circa 17th century in Java.
chemical substance Also pure substance or simply substance. A form of matter that has constant chemical composition and characteristic properties and which cannot be separated into simpler components by purely physical methods (i.e. without breaking chemical bonds). It is often called a pure substance to distinguish it from a mixture.
The possibility that dinosaurs were the ancestors of birds was first suggested in 1868 by Thomas Henry Huxley. After the work of Gerhard Heilmann in the early 20th century, the theory of birds as dinosaur descendants was abandoned in favor of the idea of them being descendants of generalized thecodonts, with the key piece of evidence being the supposed lack of clavicles in dinosaurs. However, as later discoveries showed, clavicles (or a single fused wishbone, which derived from separate clavicles) were not actually absent; they had been found as early as 1924 in Oviraptor, but misidentified as an interclavicle. In the 1970s, John Ostrom revived the dinosaur–bird theory, which gained momentum in the coming decades with the advent of cladistic analysis, and a great increase in the discovery of small theropods and early birds. Of particular note have been the fossils of the Jehol Biota, where a variety of theropods and early birds have been found, often with feathers of some type. Birds share over a hundred distinct anatomical features with other theropod dinosaurs. They are most closely allied with maniraptoran coelurosaurs. A minority of scientists, most notably Alan Feduccia and Larry Martin, have proposed other evolutionary paths, including revised versions of Heilmann's basal archosaur proposal, or that maniraptoran theropods are the ancestors of birds but themselves are not dinosaurs, only convergent with dinosaurs.
Sources: en.wikipedia.org
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.
No. It is a shortened peptide fragment, not the full hormone. It does not contain the entire hGH sequence and is studied for different proposed effects.
Regulatory approvals for weight loss are not established in major jurisdictions. Some human trials reported modest changes, but the evidence is limited, and it remains a research compound.
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.